FDA approved expanded use of Casgevy, co-developed by CRISPR Therapeutics and Vertex, for patients ages 2 and older with sickle cell disease with recurrent vaso-occlusive crises, or transfusion-dependent beta thalassemia — the first gene therapy approved for sickle cell disease patients this young (previously approved only for ages 12+).
Run-up into the decision (T-120 → T+5)
Daily close, T-120 (1/7/26) through T+5. Run-up high $61.74 on 2/26/26, low $44.34 on 3/30/26 (T-120 to T-1). FDA decision 7/1/26. Historical price action, not a forecast.
Key facts
FDA decision date2026-07-01
OutcomeApproved
Drug / candidateCasgevy (exagamglogene autotemcel)
IndicationSickle cell disease (recurrent vaso-occlusive crises) or transfusion-dependent beta thalassemia, ages 2 and older
CompanyCRISPR Therapeutics
Market-cap tierMid
120-day run-up (T-120→T-1)-5.9%
Cohort decision-day move (history)±2% median
Run-up figures are the stock's own daily closing path over the 120 trading days before the decision, from our price history. Cohort move is the historical median absolute decision-day move for this market-cap tier — history, not a prediction.